



# 4. Rokoteannoksen pohdinta

29.4.2022

19.5.2022

Terveyden ja hyvinvoinnin laitos

**Table 1. Vaccine effectiveness against hospitalisation using different definitions of hospitalisations in a) 18 to 64 year olds and b) 65 year olds and over**

		ECDS symptomatic with onset date	SUS at least 2 days with ARI code in primary field	SUS at least 2 days and either oxygen, ventilation or ICU with ARI code in primary field
<b>18 to 64</b>				
	<b>Interval</b>	<b>VE</b>	<b>VE</b>	<b>VE</b>
Dose 1	0 to 27	48.5 (12.3 to 69.7)	36.2 (-33.9 to 69.6)	
	28+	48.7 (32.8 to 60.8)	44.1 (25.6 to 58)	75 (42.4 to 89.1)
Dose 2	0 to 13	39.6 (-31.5 to 72.2)	88.9 (58.4 to 97)	
	14 to 174	54.7 (45.3 to 62.4)	69 (58.1 to 77)	86.7 (63.6 to 95.1)
	175+	34.6 (21.7 to 45.4)	56.1 (46.4 to 64)	82.3 (67.7 to 90.3)
Booster	0 to 6	63.9 (52.2 to 72.8)	74.3 (55.9 to 85)	90.7 (56 to 98.1)
	7 to 13	80.1 (73.5 to 85.1)	90.9 (83.2 to 95.1)	
	14 to 34	82.4 (78.6 to 85.6)	88.6 (84.9 to 91.5)	97.1 (92.2 to 98.9)
	35 to 69	72.7 (67.2 to 77.2)	85.8 (82.4 to 88.5)	94.3 (88.9 to 97.1)
	70 to 104	66.9 (59.1 to 73.3)	80.2 (74.9 to 84.4)	89.9 (78.3 to 95.3)
	105+	53.6 (36.9 to 65.9)	67.4 (53.1 to 77.4)	75.9 (15.8 to 93.1)
<b>65+</b>				
	<b>Interval</b>	<b>VE</b>	<b>VE</b>	<b>VE</b>
Dose 1	0 to 27		43.9 (-41 to 77.7)	
	28+		53.4 (36.3 to 65.9)	78.3 (43.7 to 91.7)
Dose 2	0 to 13			
	14 to 174	77.8 (45 to 91)	82.3 (74.3 to 87.8)	90.9 (72.6 to 97)
	175+	66.7 (43.4 to 80.4)	57.7 (49.6 to 64.4)	73.4 (55.1 to 84.3)
Booster	0 to 6	85.8 (61.5 to 94.7)	77.9 (65.3 to 85.9)	89.2 (63.1 to 96.8)
	7 to 13	92.3 (76.3 to 97.5)	84.7 (76 to 90.2)	94.7 (71.6 to 99)
	14 to 34	92.4 (86 to 95.8)	91.3 (89.1 to 93.1)	95.8 (91.3 to 97.9)
	35 to 69	87 (79.2 to 91.8)	89.3 (87.3 to 90.9)	92.8 (88.4 to 95.6)
	70 to 104	84 (74.6 to 89.9)	88.1 (86.1 to 89.9)	92.5 (88.1 to 95.2)
	105+	76.9 (60.6 to 86.4)	85.3 (82.4 to 87.6)	86.8 (77.1 to 92.3)






ECDS = Emergency Care Dataset (this analysis includes all admissions with a positive COVID-19 test via emergency care except for those coded as injuries). SUS = Secondary Users Service (this analysis includes all admissions to secondary care for >=2 days with a respiratory code in the first diagnostic field) (10).

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1070356/Vaccine-surveillance-report-week-16.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1070356/Vaccine-surveillance-report-week-16.pdf)

# Rokotesuoja > 70-v suomalaisilla


- Aineisto 897 975 yli 70-vuotiasta suomalaista
  - Labra varmistetun SARS-CoV-2 tartunnan sairastaneet poissuljettu
- Päätetapahtumat  
Sairaalahoitoa vaativa Covid-19
  - Koronan takia sairaalaan/teholle joutuneet = Päädiagnoosikoodi Covid-19 liittyvä
  - SARS-CoV-2 todettu 7 vrk ennen tai 14 vrk jälkeen sairaalaan oton
- Omikron VE = Tehokkuus 1.1–31.3.2022
  - **Tulokset päivitetty tällä viikolla**
- Vakiointi:
  - Ikä
  - Sukupuoli
  - Asunalue
  - Pitkäaikaishoidettavat
  - Influenssa rokotus 2019-2020 kaudella
  - Sairaalassa vietetyt yöt 2015-2019
  - Riskiryhmät
- Analyysi Cox-regressiolla
- $VE = 1 - HR$

**High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron**

 Ulrike Baum,  Eero Poukka,  Tuija Leino, Terhi Kilpi,  Hanna Nohynek,  Arto A. Palmu

doi: <https://doi.org/10.1101/2022.03.11.22272140>

## Suoja sairaalahoitoa vaativaa Covid-19 vastaan +70-v väestössä 1.1-31.3.2022



# Suoja sairaalahoitoa vaativaa Covid-19 vastaan +70-v väestössä 1.1-31.3.2022

